On August 28, 2019 CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody therapeutic technology platform, reported that Sean McCarthy, D.Phil., president, chief executive officer and chairman, will participate at the following healthcare conferences in September (Press release, CytomX Therapeutics, AUG 28, 2019, View Source [SID1234539056]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Citi 14ᵗʰ Annual Biotech Conference
Panel Discussion: New Targets in Cancer Immunotherapy and the Tumor Microenvironment
Date: Wednesday, September 4, 2019
Time: 9:30 a.m. ET
Location: Boston, Massachusetts

H. C. Wainwright 21st Annual Global Investment Conference
Date: Tuesday, September 10, 2019
Time: 10:50 a.m. ET
Location: New York, New York
Live audio webcast of the panel discussion and corporate presentation will be available through the "Investors & News" section of CytomX’s website. An archived replay will be available for 60 days following the event.